Valuation: Niagen Bioscience, Inc.

Market Cap 263M 229M 212M 196M 369M 25.22B 376M 2.53B 993M 12.35B 986M 965M 42.52B P/E 2026 *
14.5x
P/E 2027 * 11.6x
Enterprise Value 263M 229M 212M 196M 369M 25.22B 376M 2.53B 993M 12.35B 986M 965M 42.52B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 1.58x
Free-Float
70.74%
Yield 2026 *
-
Yield 2027 * -
1 day-5.19%
1 week-4.64%
Current month+3.13%
1 month-4.64%
3 months-29.85%
6 months-47.86%
Current year-48.27%
1 week 3.28
Extreme 3.28
3.54
1 month 3.18
Extreme 3.175
3.64
Current year 3.18
Extreme 3.175
6.86
1 year 3.18
Extreme 3.175
11.58
3 years 1.25
Extreme 1.25
14.69
5 years 1.15
Extreme 1.15
14.69
10 years 1.15
Extreme 1.15
23.66
Manager TitleAgeSince
Chief Executive Officer 66 01/06/2018
Director of Finance/CFO 35 21/10/2024
Chief Tech/Sci/R&D Officer - 01/07/2020
Director TitleAgeSince
Chairman 57 22/06/2018
Director/Board Member 66 09/07/2015
Director/Board Member 65 27/03/2017
Date Insider Type Main position Quantity % Market Cap.
30/06Free

General Counsel

2,314 0.0029%
30/06Free

Chief Executive Officer

1,106 0.0014%
30/06Free

Chief Financial Officer

4,255 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
-5.19%-4.64%-70.78%+103.09% 277M
-1.05%+1.39%+3.15%+6.98% 50.61B
+0.55%-2.88%+382.07%+593.81% 39.11B
+0.13%-0.19%+29.79%-6.00% 34.64B
+0.86%-0.78%+21.58%+56.15% 33.79B
-1.31%-3.03%+2.51%+25.24% 26.89B
+0.13%-0.52% - - 16.47B
+1.13%-1.85%+67.36%+120.46% 15.14B
-0.72%+0.12%+14.69%+16.95% 13.85B
+1.13%-0.44%+12.34%-31.79% 12.72B
Average -0.43%-1.33%+51.41%+98.32% 24.35B
Weighted average by Cap. -0.05%-0.91%+80.57%+121.69%

Financials

2026 *2027 *
Net sales 143M 125M 115M 106M 200M 13.7B 204M 1.37B 539M 6.71B 536M 524M 23.09B 166M 145M 134M 124M 233M 15.94B 237M 1.6B 627M 7.8B 623M 609M 26.87B
Net income 18.98M 16.59M 15.33M 14.17M 26.68M 1.82B 27.16M 183M 71.74M 893M 71.29M 69.71M 3.07B 23.82M 20.81M 19.24M 17.77M 33.47M 2.29B 34.08M 229M 90.02M 1.12B 89.45M 87.48M 3.86B
Net Debt - -
Logo Niagen Bioscience, Inc.
Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
Employees
117
Date Price Change Volume
14/07/26 USD 3.290 -5.19% 861,925
13/07/26 USD 3.470 +2.36% 1,105,997
10/07/26 USD 3.390 -2.87% 400,284
09/07/26 USD 3.490 +3.56% 646,001
08/07/26 USD 3.370 -2.32% 1,005,333
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.290USD
Average target price
12.00USD
Spread / Average Target
+264.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NAGE Stock